Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19. Brain Sci. 2020, 10.
Uncategorised
Legge SE, Walters JT.
Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective, Pharmacogenomics. 2019;20:279–290. doi: 10.2217/pgs-2018-0188
Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, Samer CF, Lieberman JA, Villard J.
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The Pharmacogenomics Journal. 2019;19:211-218
Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR.
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry. 2011;72:458-63.
Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS.
An evaluation of the variation and underuse of clozapine in the United Kingdom. Acta Psychiatr Scand. 2021;00:1–9
Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, Lieberman JA, Daly MJ, Sullivan PF.
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.
Lacaze P, Ronaldson KJ, Zhang EJ, Alfirevic A, Shah H, Newman L, Strahl M, Smith M, Bousman C, Francis B, Morris AP, Wilson T, Rossello F, Powell D, Vasic V, Sebra R, McNeil JJ, Pirmohamed M.
Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry. 2020;10:37